Clinical trials: Metabolism and Excretion
Opioid Use Disorder
Single Dose Study of [14C]-IDV184001AN ([14C]-IDV184001) in Healthy Adult Male Participants
The purpose of this open label study is to characterise the absorption, metabolism, excretion, and mass balance of [14C]-IDV184001AN ([14C]-IDV184001) in healthy adult male participants.
- Trial name
- NCT05974046
- Testing
- [14C]IDV184001AN
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Indivior Inc.
Insomnia
A Study To Investigate The Absorption, Metabolism And Excretion Of [14C] PD 0200390 In Six Healthy Male Volunteers
To determine the mass balance of PD 0200390
- Trial name
- NCT00722306
- Testing
- PD 0200390
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pfizer
Sleep Initiation and Maintenance Disorders
Radiolabel Study In Healthy Volunteers For Insomnia-Targeting Drug
The purpose of this study is to define the absorption, breakdown and excretion of a single dose of radiolabelled SB-649868 and its breakdown products by measuring their concentration in blood, urine and faeces over a 7-10 day…
- Trial name
- NCT00520663
- Testing
- 14C-SB649868
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Advanced Solid Tumors
Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients
The purpose of this study is to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer patients.
- Trial name
- NCT02622932
- Testing
- Anlotinib and 14C-labeled Anlotinib
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Healthy
A Study to Understand How a Study Medicine Called PF-07328948 is Absorbed and Processed in the Body of Healthy Male Adults
The purpose of this study is to learn how a certain amount of [14C] PF-07320948 is taken up into the bloodstream and removed from the body.
- Trial name
- NCT07508228
- Testing
- Oral [14C]PF-07328948, Oral Unlabeled PF-07328948, IV [14C]PF-07328948
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Pfizer
HIV Infections
Pharmacokinetics and Metabolism of 14 Carbon [14C]-GSK3640254
This is an open-label, single-center, single group, non-randomized, two-period, single sequence, mass balance study which will enroll 6 healthy male participants.
- Trial name
- NCT04507321
- Testing
- GSK3640254 Oral tablet, [14C]-GSK3640254 intravenous infusion, [14C]-GSK3640254 powder
- Where
- United Kingdom
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Solid Tumors
An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors
The main aim of this study is to assess how the human body of adults with advanced or metastatic solid tumors absorbs, distributes, metabolizes and excretes subasumstat following a single 1 hour infusion of subasumstat.
- Trial name
- NCT05976334
- Testing
- [14C] Subasumstat, Subasumstat
- Where
- 2 sites in Hungary
- Volunteers
- 3 people
- Sponsor
- Takeda
Healthy Participants
Study Investigating a Single Oral Dose of Fenebrutinib in Healthy Volunteers
The purpose of this study is to determine the excretion kinetics and mass balance of fenebrutinib in healthy male subjects.
- Trial name
- NCT03596632
- Testing
- Fenebrutinib
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Healthy Male Participants
A Study to Evaluate the Drug Levels, Metabolism, and Removal of BMS-986322 in Healthy Adult Male Participants
The purpose of this study is to evaluate the drug levels, metabolism, and removal of BMS-986322 in healthy adult male participants.
- Trial name
- NCT06088264
- Testing
- BMS-986322
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Obesity
Effect of Dietary Components on Gastrointestinal Side Effects Induced by Orlistat, a Lipase Inhibitor
The objective of the Orlifat trial is to investigate if dietary fibres from linseeds and dairy calcium (Capolac ®) may reduce gastrointestinal side effects related to increased fecal fat content, induced by treatment with Alli®…
- Trial name
- ORLIFAT (NCT01320228)
- Testing
- Control, Capolac, Flax fiber
- Where
- Denmark
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Healthy
Oat Phenolics Bioavailability
A diet rich in whole grain is inversely associated with cardiovascular disease risk and this benefit could be partly attributed to the phenolic acid content of whole grains.
- Trial name
- NCT02574039
- Testing
- Oat bran, refined grain
- Where
- United Kingdom
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- University of Reading
Healthy
Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers
The purpose of this study is to gain an understanding of how the experimental anti-cancer drug, rigosertib, is metabolized in the body and excreted in the urine and feces after it is given as an intravenous infusion.
- Trial name
- NCT02030639
- Testing
- rigosertib
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Traws Pharma, Inc.
Healthy
A Study Investigating the Excretion Balance, Pharmacokinetics and Metabolism of a Single Oral Dose of [14C]-Labeled Risdiplam (RO7034067) in Healthy Male Participants
This is an open-label, non-randomized study investigating the excretion balance, PK and metabolism of a single oral dose of [14C]-labeled Risdiplam (RO7034067) in healthy male participants.
- Trial name
- NCT03036501
- Testing
- [^14C]-Risdiplam
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Healthy
A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People
The purpose of this clinical trial is to learn if the study medicine (called PF-07817883) is safe and how it goes in and out of the body in healthy people. PF-07817883 is for the potential treatment of COVID-19.
- Trial name
- NCT05580003
- Testing
- PF-07817883, Midazolam, Moxifloxacin
- Where
- 2 sites in United States, Belgium
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-HU6
This is a single-center, non-randomized, open-label Phase 1 study to characterize the absorption, metabolism, excretion, mass balance, pharmacokinetics (PK), safety and tolerability of HU6 following administration of a single…
- Trial name
- NCT06325930
- Testing
- [14C]-HU6
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Rivus Pharmaceuticals, Inc.
Healthy
A Study to Assess the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of (14C) Radiolabeled JNJ--42756493 to Healthy Male Participants
The purpose of this study is to assess the absorption, metabolism, and excretion of JNJ-42756493 in healthy male adult participants after administration of a single oral dose of 12 milligram (mg) of unlabeled JNJ-42756493 admixed…
- Trial name
- NCT02692677
- Testing
- JNJ-42756493
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy Volunteer
A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500
The purpose of this study is to: 1. Assess the mass balance (i.e., the cumulative elimination of 14C-related material in urine and feces, compared to the administered amount of radioactive isotope) of [14C]-EDG-7500 following a…
- Trial name
- NCT06738836
- Testing
- [14C]-EDG-7500
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Edgewise Therapeutics, Inc.
Obesity
A Phase I Study to Investigate the ADME of KD101
A Phase I Study to Investigate the Absorption, Metabolism, and Excretion of KD101 in Male Subjects
- Trial name
- NCT02819934
- Testing
- KD101
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Solid Malignancies
Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase
This Phase 1, open label, single centre, non-randomised study in patients with advanced solid malignancies consists of two parts: 1.
- Trial name
- 14C (NCT02640755)
- Testing
- [14C]AZD2014, Multiple dose AZD2014, Fulvestrant
- Where
- United Kingdom
- Volunteers
- 4 people
- Sponsor
- AstraZeneca
Dyslipidemia
ADME Study in Healthy Male Subjects With TA-8995
A study to measure the absorption, metabolism and excretion of a single dose of radiolabelled TA-8995 (10mg) in healthy male subjects.
- Trial name
- NCT02408055
- Testing
- TA-8995
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Xention Ltd